A PHASE 2a, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, DOSE-CONFIRMATION STUDY TO EVALUATE THE SAFETY, REACTOGENICITY, AND IMMUNOGENICITY OF MRNA-1273 SARS-COV-2 VACCINE IN ADULTS AGED 18 YEARS A

Administered By

Awarded By

Contributors

Start/End

  • May 1, 2021 - June 30, 2022